Bone Changes During Growth in Patients with Osteogenesis Imperfecta

被引:0
|
作者
Burgueno-Torres, Laura [1 ]
Garcia-Boedo, Lara [1 ]
de Nova-Garcia, Manuel Joaquin [1 ]
机构
[1] Univ Complutense Madrid, Fac Dent, Dent Clin Specialties Dept, Madrid 28040, Spain
关键词
osteogenesis imperfecta; biphosphonates; orthopantomography; panoramic index; pediatric patient; PANORAMIC MANDIBULAR INDEXES; RADIOMORPHOMETRIC INDEXES; FRACTAL DIMENSION; CHILDREN; PAMIDRONATE; THERAPY; DENSITY; DIAGNOSIS; GENDER; CORTEX;
D O I
10.3390/jcm14051764
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Objectives: Osteogenesis Imperfecta (OI) is a congenital disorder, in which the production of collagen, mainly type I, is altered, leading to a decrease in bone mineral density, increasing the risk of fracture with minimal trauma. Several studies have analyzed bone mineral density in osteoporotic patients based on linear measurements such as radiomorphometric indices measured with panoramic radiographs, although few studies have investigated bone trabeculation in children diagnosed with OI. Therefore, the aim of the present investigation was to analyze the dental panoramic indices in panoramic radiographs in the cortical and trabeculated bone of children with OI. Methods: Thus, 66 pediatric patients diagnosed with OI under antiresorptive treatment were compared with a sample of controls matched for sex and age. Using Image J software (version: 1.54d), three radiomorphometric indices were analyzed in orthopantomographies of the study and control groups, evaluating the influence of disease severity as well as the type of antiresorptive treatment administered. Results: Patients with OI had a higher presence of type C2 and C3 MCI (mandibular cortical index) than their matched controls (p < 0.05), although no differences were found for the visual estimation of cortical width (SVE) and mandibular cortical width (MCW). Treatment with zoledronic acid was associated with a higher number of cases of type C1 MCI, in terms of sample description, while patients treated with a combination of pamidronate and zoledronic acid had a higher rate of type C1 and C2 MCI, with no statistical differences. Conclusions: In the overall sample, most patients showed a thin SVE index (59.1%), a C2 or C1 type MCI (46.2% and 42.4%) and an MCW of 2.9 mm. Differences in bone mineral density were also observed throughout growth and the different antiresorptive treatments. Zoledronic acid has been associated with a higher percentage of C1 and C3 ICM, and pamidronate alone or in combination is associated with a C1 and C2 MCI index.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Temporal bone imaging in osteogenesis imperfecta patients with hearing loss
    Swinnen, Freya K. R.
    Casselman, Jan W.
    De Leenheer, Els M. R.
    Cremers, Cor W. R. J.
    Dhooge, Ingeborg J. M.
    LARYNGOSCOPE, 2013, 123 (08) : 1988 - 1995
  • [32] Calvaria Bone Transcriptome in Mouse Models of Osteogenesis Imperfecta
    Moffatt, Pierre
    Boraschi-Diaz, Iris
    Marulanda, Juliana
    Bardai, Ghalib
    Rauch, Frank
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (10)
  • [33] Osteogenesis Imperfecta and Bone Marrow Transplant
    Madonia, Lara
    JOURNAL OF PEDIATRIC ONCOLOGY NURSING, 2012, 29 (01) : 37 - 44
  • [34] Correlation of Bone Mineral Density on Quality of Life in Patients with Osteogenesis Imperfecta during Treatment with Denosumab
    Hoyer-Kuhn, Heike
    Starke, Christina
    Franklin, Jeremy
    Schoenau, Eckhard
    Semler, Oliver
    PEDIATRIC ENDOCRINOLOGY REVIEWS PER, 2017, 15 : 123 - 129
  • [35] Bone mass and mineralization in osteogenesis imperfecta
    Fratzl-Zelman, Nadja
    Misof, Barbara M.
    Klaushofer, Klaus
    Roschger, Paul
    WIENER MEDIZINISCHE WOCHENSCHRIFT, 2015, 165 (13-14) : 271 - 277
  • [36] Efficacy and Safety of Denosumab Therapy for Osteogenesis Imperfecta Patients with Osteoporosis-Case Series
    Kobayashi, Tsukasa
    Nakamura, Yukio
    Suzuki, Takako
    Yamaguchi, Tomomi
    Takeda, Ryojun
    Takagi, Masaki
    Hasegawa, Tomonobu
    Kosho, Tomoki
    Kato, Hiroyuki
    JOURNAL OF CLINICAL MEDICINE, 2018, 7 (12)
  • [37] Osteogenesis imperfecta
    Semler, O.
    Hoyer-Kuhn, H.
    Netzer, C.
    MEDIZINISCHE GENETIK, 2012, 24 (04) : 297 - 311
  • [38] Osteogenesis imperfecta
    Ibanez, Angelica
    Hodgson, Felipe
    REVISTA MEDICA CLINICA LAS CONDES, 2021, 32 (03): : 311 - 318
  • [39] Effects of Long-Term Pamidronate Treatment on Bone Density and Fracture Rate in 65 Osteogenesis Imperfecta Patients
    Yazan, Hakan
    Gunes, Nilay
    Akpinar, Evren
    Yildirim, Timur
    Ozyalvac, Osman Nuri
    Akkaya, Dilek Uludag
    Tuysuz, Beyhan
    TURKISH ARCHIVES OF PEDIATRICS, 2021, 56 (05): : 474 - 478
  • [40] Gender-Related Impact of Sclerostin Antibody on Bone in the Osteogenesis Imperfecta Mouse
    Cardinal, Mickael
    Chretien, Antoine
    Roels, Thomas
    Lafont, Sebastien
    Ominsky, Michael S.
    Devogelaer, Jean-Pierre
    Manicourt, Daniel H.
    Behets, Catherine
    FRONTIERS IN GENETICS, 2021, 12